Astria Therapeutics Aktie

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025. Markus Magerl, M.D., Professor of Dermatology and Allergy at the Charité Universitätsmedizin Berlin Institut.» Mehr auf businesswire.com

Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation.» Mehr auf seekingalpha.com

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 shares of Astria's common stock on February 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gra.» Mehr auf businesswire.com